Author:
Jacqmin Philippe,McFadyen Lynn,Wade Janet R.
Subject
Pharmacology (medical),Pharmacology
Reference25 articles.
1. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
2. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
3. 3M McHale, S Abel, D Russell, J Gallagher, and E van der Ryst . Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427 857). In: 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005 July 24-27. Rio de Janeiro, Brazil.
4. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
5. A Pharmacokinetic-Pharmacodynamic Model to Optimize the Phase IIa Development Program of Maraviroc
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献